AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28877711 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon nanoparticles 10 μg, 50 μg, or 100 μg
Number of subjects: 26
Study 28877711 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon nanoparticles 100 μg
Number of subjects: 26
Study 28877711 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 26
Study 25440688 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS‐FNA using 19GN
Number of subjects: 100
Study 23645695 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (100 mg/kg tid)
Number of subjects: 38
Study 23645695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 21164372 — intervention group
Group type: EXPERIMENTAL
Intervention: ICGA (intraoperative near-infrared indocyanine green angiography)
Number of subjects: 104
Study 21164372 — intervention group
Group type: COMPARATOR
Intervention: Microvascular Doppler ultrasound
Number of subjects: 104
Study 21164372 — intervention group
Group type: COMPARATOR
Intervention: Neuroendoscopy
Number of subjects: 104
Study 21164372 — intervention group
Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 104
Study 21164372 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of DSA and ICGA
Number of subjects: 104
Study 18347491 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (cephalexin)
Number of subjects: 146
Study 18347491 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 146
Study 17227516 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsated small-caliber endoscopy
Number of subjects: 121
Study 17227516 — intervention group
Group type: COMPARATOR
Intervention: Conventional endoscopy
Number of subjects: 121
Study 15530757 — intervention group
Group type: EXPERIMENTAL
Intervention: Action plan intervention
Number of subjects: 88
Study 15530757 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 88
Study 11502832 — intervention group
Group type: EXPERIMENTAL
Intervention: High telomerase activity during the proliferative phase.
Number of subjects: 72
Study 11502832 — intervention group
Group type: EXPERIMENTAL
Intervention: High telomerase activity at the onset of the luteal phase.
Number of subjects: 72
Study 11502832 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased telomerase activity during the early luteal phase.
Number of subjects: 72
Study 11502832 — intervention group
Group type: EXPERIMENTAL
Intervention: Telomerase activity disappeared by the midluteal phase.
Number of subjects: 72
Study 11502832 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate telomerase activity in the late luteal phase.
Number of subjects: 72
Study 11502832 — intervention group
Group type: EXPERIMENTAL
Intervention: Inversely related serum progesterone levels to telomerase activity.
Number of subjects: 72
Study 11502832 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic changes in endometrial telomerase activity during the menstrual cycle.
Number of subjects: 72
Study 11502832 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship between sex steroid levels and telomerase regulation.
Number of subjects: 72
Study 9423946 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 110
Study 9423946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 7516378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CPA) plus Tamoxifen (TAM)
Number of subjects: 256
Study 7516378 — intervention group
Group type: EXPERIMENTAL
Intervention: CPA plus Serenoa Repens
Number of subjects: 256
Study 3544968 — intervention group
Group type: EXPERIMENTAL
Intervention: TECA 120 mg/day
Number of subjects: 94
Study 3544968 — intervention group
Group type: EXPERIMENTAL
Intervention: TECA 60 mg/day
Number of subjects: 94
Study 3544968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 31994196 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine mesylate (1.7-mL OraVerse, 0.4-mg)
Number of subjects: 66
Study 31994196 — intervention group
Group type: COMPARATOR
Intervention: Control (1.7-mL sterile saline water)
Number of subjects: 66
Study 29651711 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 45-60 mg/day for 3 months (n=37)
Number of subjects: 107
Study 29651711 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU, n=70)
Number of subjects: 107
Study 28003052 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 39
Study 28003052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 25204553 — intervention group
Group type: EXPERIMENTAL
Intervention: pertuzumab-trastuzumab-docetaxel (PTD)
Number of subjects: 417
Study 25204553 — intervention group
Group type: COMPARATOR
Intervention: trastuzumab-docetaxel (TD)
Number of subjects: 417
Study 23609186 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy (BCT) after EBRT-CT
Number of subjects: 211
Study 23609186 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical hysterectomy (RH) after EBRT-CT
Number of subjects: 211
Study 19902491 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents with IVUS guidance
Number of subjects: 210
Study 19902491 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stents without IVUS guidance
Number of subjects: 210
Study 19055847 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 540
Study 19055847 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulation (Control)
Number of subjects: 540
Study 17259789 — intervention group
Group type: EXPERIMENTAL
Intervention: T4-Ibsa oral solution
Number of subjects: 24
Study 17259789 — intervention group
Group type: COMPARATOR
Intervention: Eutirox 100 tablets
Number of subjects: 24
Study 17259789 — intervention group
Group type: EXPERIMENTAL
Intervention: T3-Ibsa oral solution
Number of subjects: 24
Study 17259789 — intervention group
Group type: COMPARATOR
Intervention: Ti-tre tablets
Number of subjects: 24
Study 12749488 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets (ITNs)
Number of subjects: 833
Study 10800972 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-based bedside counseling program supplemented with a videotape, self-help materials, and a follow-up telephone call
Number of subjects: 1173
Study 10800972 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1173
Study 8630380 — intervention group
Group type: EXPERIMENTAL
Intervention: PIXY321, 375 microg/m2 twice a day subcutaneously
Number of subjects: 53
Study 8630380 — intervention group
Group type: COMPARATOR
Intervention: GM-CSF, 250 microg/m2 daily subcutaneously
Number of subjects: 53
Study 8630380 — intervention group
Group type: EXPERIMENTAL
Intervention: PIXY321
Number of subjects: 53
Study 8630380 — intervention group
Group type: COMPARATOR
Intervention: GM-CSF
Number of subjects: 53
Study 1343144 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant CMF or TMF chemotherapy
Number of subjects: 569
Study 1343144 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant treatment with adrioblastin
Number of subjects: 569
Study 1343144 — intervention group
Group type: COMPARATOR
Intervention: CMF and TMF chemotherapy
Number of subjects: 569
Study 4068237 — intervention group
Group type: EXPERIMENTAL
Intervention: N-CWS immunotherapy
Number of subjects: 276
Study 4068237 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 276
Study 30232083 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive sampling of the tubes for STICs/STILs/p53 signatures
Number of subjects: 479
Study 27981924 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (100 mg per night, increased to 200 mg if needed)
Number of subjects: 78
Study 27981924 — intervention group
Group type: COMPARATOR
Intervention: Control group (received 10 mg azasetron before chemotherapy)
Number of subjects: 78
Study 24882841 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine kinesiotherapy (using a portable device and telemonitoring infrastructure)
Number of subjects: 40
Study 24882841 — intervention group
Group type: COMPARATOR
Intervention: Control kinesiotherapy (using common daily-life objects)
Number of subjects: 40
Study 22817102 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and post-operative orthogeriatric care
Number of subjects: 332
Study 19525335 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone 1-3 mg
Number of subjects: 0
Study 19525335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18718641 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg/d) for 2 weeks
Number of subjects: 307
Study 18718641 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg/d) for 1 month
Number of subjects: 307
Study 18718641 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg/d) for 3 months
Number of subjects: 307
Study 18718641 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg/d) for 4 months
Number of subjects: 307
Study 18718641 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg/d) for 1-4 months
Number of subjects: 307
Study 18718641 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg/d)
Number of subjects: 307
Study 18718641 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo/surgery)
Number of subjects: 307
Study 15823654 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand rubbing with an alcoholic solution
Number of subjects: 50
Study 15823654 — intervention group
Group type: COMPARATOR
Intervention: Handwashing with unmedicated soap
Number of subjects: 50
Study 11983645 — intervention group
Group type: EXPERIMENTAL
Intervention: Work and Social Adjustment Scale (WSAS)
Number of subjects: 0
Study 10099965 — intervention group
Group type: EXPERIMENTAL
Intervention: buserelin
Number of subjects: 60
Study 10099965 — intervention group
Group type: EXPERIMENTAL
Intervention: nafarelin
Number of subjects: 60
Study 10099965 — intervention group
Group type: EXPERIMENTAL
Intervention: leuprorelin
Number of subjects: 60
Study 7776647 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-serving attributors in the conjunctive-task condition
Number of subjects: 24
Study 7776647 — intervention group
Group type: EXPERIMENTAL
Intervention: Additive-task participants
Number of subjects: 24
Study 2170820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of angiotensin II (AII)
Number of subjects: 7
Study 2170820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 85812 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aminoacid infusion
Number of subjects: 30
Study 85812 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hyperalimentation
Number of subjects: 30
Study 85812 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 30
Study 31804285 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert modeling
Number of subjects: 73
Study 31804285 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice-over PowerPoint
Number of subjects: 73
Study 31804285 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading assignments
Number of subjects: 73
Study 31131617 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose 2 g/day for 2 weeks
Number of subjects: 52
Study 31131617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 28489214 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial Cellulose (BC) membrane dressings
Number of subjects: 25
Study 28489214 — intervention group
Group type: COMPARATOR
Intervention: Triglyceride oil dressings
Number of subjects: 25
Study 25530275 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone (group P)
Number of subjects: 88
Study 25530275 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol combined with 40% nitrous oxide inhalation (group N+P)
Number of subjects: 88
Study 24197662 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (4+ years)
Number of subjects: 690
Study 24197662 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (<4 years)
Number of subjects: 690
Study 22044787 — intervention group
Group type: EXPERIMENTAL
Intervention: Active navigation
Number of subjects: 44
Study 22044787 — intervention group
Group type: COMPARATOR
Intervention: Passive navigation
Number of subjects: 44
Study 19497559 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine alone
Number of subjects: 224
Study 19497559 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification alone
Number of subjects: 224
Study 19497559 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 224
Study 19497559 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine plus brief lifestyle modification
Number of subjects: 224
Study 19497559 — intervention group
Group type: EXPERIMENTAL
Intervention: Early weight loss
Number of subjects: 224
Study 19497559 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss success at 1 year
Number of subjects: 224
Study 17760540 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrush and triclosan/copolymer/fluoride-containing dentifrice
Number of subjects: 160
Study 17760540 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush and standard fluoride-containing dentifrice
Number of subjects: 160
Study 11036118 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 404
Study 11036118 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 404
Study 8796365 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone treatment for 6 months
Number of subjects: 20
Study 1636873 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine (3 x 500 mg for one day)
Number of subjects: 74
Study 1636873 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine (3 x 500 mg for one day + additional treatment on day 7)
Number of subjects: 74
Study 1636873 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine (both regimens)
Number of subjects: 74
Study 6148024 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated clothing
Number of subjects: 0
Study 6148024 — intervention group
Group type: EXPERIMENTAL
Intervention: Deet applied to exposed skin
Number of subjects: 0
Study 6148024 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of permethrin-treated clothing and deet
Number of subjects: 0
Study 6148024 — intervention group
Group type: COMPARATOR
Intervention: Untreated clothing
Number of subjects: 0
Study 6148024 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated uniforms
Number of subjects: 0
Study 30721652 — intervention group
Group type: EXPERIMENTAL
Intervention: Premature Infant Oral Motor Intervention (PIOMI) once daily for 7 consecutive days
Number of subjects: 30
Study 30721652 — intervention group
Group type: COMPARATOR
Intervention: Routine care only (Control)
Number of subjects: 30
Study 29608461 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone
Number of subjects: 2218
Study 29608461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2218
Study 26650971 — intervention group
Group type: EXPERIMENTAL
Intervention: RBP-6000 (300 mg)
Number of subjects: 0
Study 26650971 — intervention group
Group type: COMPARATOR
Intervention: Hydromorphone (6 mg, 18 mg)
Number of subjects: 0
Study 24952866 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial PCI
Number of subjects: 0
Study 24952866 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral PCI
Number of subjects: 0
Study 22677307 — intervention group
Group type: EXPERIMENTAL
Intervention: Azomac® (Test formulation)
Number of subjects: 24
Study 22677307 — intervention group
Group type: COMPARATOR
Intervention: Zithromax® (Reference product)
Number of subjects: 24
Study 20722559 — intervention group
Group type: EXPERIMENTAL
Intervention: Checking renal function in all patients prior to angiography
Number of subjects: 291
Study 20722559 — intervention group
Group type: EXPERIMENTAL
Intervention: Checking both estimated glomerular filtration rate (eGFR) and serum creatinine (SCr)
Number of subjects: 291
Study 20722559 — intervention group
Group type: EXPERIMENTAL
Intervention: Checking serum creatinine (SCr) alone
Number of subjects: 291
Study 20722559 — intervention group
Group type: EXPERIMENTAL
Intervention: Checking estimated glomerular filtration rate (eGFR) alone
Number of subjects: 291
Study 20722559 — intervention group
Group type: EXPERIMENTAL
Intervention: Checking albumin-to-creatinine (A-C) ratio
Number of subjects: 291
Study 20722559 — intervention group
Group type: EXPERIMENTAL
Intervention: Considering eGFR level less than 60 mL/min/1.73 m² as high risk for CIN
Number of subjects: 291
Study 20722559 — intervention group
Group type: EXPERIMENTAL
Intervention: Considering eGFR level less than 30 mL/min/1.73 m² as high risk for CIN
Number of subjects: 291
Study 20722559 — intervention group
Group type: EXPERIMENTAL
Intervention: Using only isosmolar media in high-risk patients
Number of subjects: 291
Study 20722559 — intervention group
Group type: EXPERIMENTAL
Intervention: Using only low osmolar media in high-risk patients
Number of subjects: 291
Study 20722559 — intervention group
Group type: EXPERIMENTAL
Intervention: Using either isosmolar or low osmolar media in high-risk patients
Number of subjects: 291
Study 18587501 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 15793048 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based exercise program (3 sessions per week)
Number of subjects: 136
Study 15793048 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise program (3 sessions per week)
Number of subjects: 136
Study 12594972 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture applied to tender points once a week for 3 weeks.
Number of subjects: 34
Study 12594972 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (no needle insertion) applied to tender points once a week for 3 weeks.
Number of subjects: 34
Study 10073841 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin K1
Number of subjects: 0
Study 10073841 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous vitamin K1
Number of subjects: 0
Study 7721614 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol 40 mg three times per day by mouth
Number of subjects: 198
Study 7721614 — intervention group
Group type: COMPARATOR
Intervention: Diethylstilbestrol 1 mg three times per day by mouth
Number of subjects: 198
Study 7721614 — intervention group
Group type: COMPARATOR
Intervention: Diethylstilbestrol (DES)
Number of subjects: 198
Study 7721614 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol
Number of subjects: 198
Study 2047898 — intervention group
Group type: EXPERIMENTAL
Intervention: Active partner condition
Number of subjects: 114
Study 2047898 — intervention group
Group type: COMPARATOR
Intervention: Passive partner condition
Number of subjects: 114
Study 2047898 — intervention group
Group type: EXPERIMENTAL
Intervention: Home monitoring (immediate)
Number of subjects: 114
Study 2047898 — intervention group
Group type: COMPARATOR
Intervention: Home monitoring (delayed)
Number of subjects: 114
Study 30678676 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended access to the Big White Wall (BWW) for 3 months (n=55)
Number of subjects: 233
Study 30678676 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of access to the Big White Wall (BWW) (n=57)
Number of subjects: 233
Study 29432076 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy using paclitaxel and carboplatin (3 cycles, once every 3 weeks) followed by radical hysterectomy
Number of subjects: 633
Study 29432076 — intervention group
Group type: COMPARATOR
Intervention: Concomitant chemoradiation with standard cisplatin-based treatment (once every week for 5 weeks)
Number of subjects: 633
Study 29432076 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy plus surgery
Number of subjects: 633
Study 29432076 — intervention group
Group type: COMPARATOR
Intervention: Concomitant chemoradiation
Number of subjects: 633
Study 26694501 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Training (CT) - 4 sets of 30-s maximal effort, separated by 4 m 30-s rest intervals
Number of subjects: 20
Study 26694501 — intervention group
Group type: COMPARATOR
Intervention: Resistance Training (RT) - 3 sets × 10 repetitions at 80% 1RM of arm-curl exercise, performed 3 times per week for 8 weeks
Number of subjects: 20
Study 24788282 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary coaching
Number of subjects: 0
Study 23654003 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg administered 1 hour and 24 hours after phacoemulsification (Group I)
Number of subjects: 53
Study 23654003 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group II) without acetazolamide
Number of subjects: 53
Study 23654003 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg (Group I)
Number of subjects: 53
Study 20591614 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritually Integrated Treatment (SIT)
Number of subjects: 125
Study 20591614 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 125
Study 20591614 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control (WLC)
Number of subjects: 125
Study 17956647 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA+DHA supplementation (1.5 g/d)
Number of subjects: 190
Study 17956647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 16438453 — intervention group
Group type: EXPERIMENTAL
Intervention: Validated Arabic version of the WHO‐ILAR COPCORD Core Questionnaire
Number of subjects: 5159
Study 16438453 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up for one year with phone calls every 2 weeks
Number of subjects: 5159
Study 12449209 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer Assisted Instruction (CAI) module on radiographic technique
Number of subjects: 59
Study 12449209 — intervention group
Group type: EXPERIMENTAL
Intervention: Students who used the CAI module
Number of subjects: 59
Study 12449209 — intervention group
Group type: COMPARATOR
Intervention: Students who did not view the CAI CD
Number of subjects: 59
Study 10602978 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium filtration (0.1 mm added to standard filtration)
Number of subjects: 21
Study 8751166 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen saturation (Sao2) before medication
Number of subjects: 74